MétaCan
Menu
Back to cohort
Record W4309247748 · doi:10.1002/ejhf.2738

<scp>Health‐related</scp> quality of life outcomes in <scp>PARAGON‐HF</scp>

2022· article· en· W4309247748 on OpenAlexaff
Alvin Chandra, Carísi Anne Polanczyk, Brian Claggett, Muthiah Vaduganathan, Milton Packer, Martin Lefkowitz, Jean L. Rouleau, Jiankang Liu, Victor Shi, H. Schwende, Michael R. Zile, Akshay S. Desai, Marc A. Pfeffer, John J.V. McMurray, Scott D. Solomon, Eldrin F. Lewis

Bibliographic record

VenueEuropean Journal of Heart Failure · 2022
Typearticle
Languageen
FieldMedicine
TopicCardiovascular Function and Risk Factors
Canadian institutionsUniversité de MontréalMontreal Heart Institute
FundersRespicardiaSanofi PasteurNational Institutes of HealthServierModernaSarepta TherapeuticsAlnylam PharmaceuticalsCytokineticsAmerican RegentSanofiMyoKardiaNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationAstraZenecaEli Lilly and CompanyDaiichi-SankyoAmgen
KeywordsMedicineSacubitrilValsartanSacubitril, ValsartanConfidence intervalInternal medicineOdds ratioEjection fractionQuality of life (healthcare)Heart failureRandomizationRandomized controlled trialMinimal clinically important differenceCardiologyBlood pressure

Abstract

fetched live from OpenAlex

AIMS: Heart failure (HF) is associated with poor health-related quality of life (HRQL). Patients with HF with preserved ejection fraction (HFpEF) have similar HRQL impairment as those with reduced ejection fraction. This study describes the impact of sacubitril/valsartan on HRQL in patients with HFpEF enrolled in the PARAGON-HF trial. METHODS AND RESULTS: Patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQol (EQ-5D) at randomization, 4, 8 months, and annually thereafter. Changes in HRQL scores were evaluated using repeated measures models adjusted for treatment, baseline values and region. The pre-specified principal efficacy assessment was at 8 months at which time patients randomized to sacubitril/valsartan had borderline higher KCCQ clinical summary score (CSS) with least squares mean (LSM) adjusted difference of 1.0 (95% confidence interval [CI] 0.0, 2.1; p = 0.051). Including all visits up to 36 months, the LSM difference in KCCQ-CSS favoured sacubitril/valsartan with average adjusted difference of 1.1 (95% CI 0.1, 2.0; p = 0.034). Patients treated with sacubitril/valsartan had greater odds of clinically meaningful improvement (≥5-point increase) in KCCQ-CSS (odds ratio 1.31; 95% CI 1.06, 1.61) at 8 months. At 8 months, there was no significant difference in the EQ visual analogue scale between the treatment arms, but sacubitril/valsartan was associated with higher EQ-5D utility score (US-based) with LSM adjusted difference of 0.01 (95% CI 0.00, 0.02; p = 0.019). CONCLUSION: Compared with valsartan, sacubitril/valsartan had a borderline benefit on KCCQ-CSS at 8 months in patients with HFpEF. This benefit became more significant when data from all visits up to 36 months were included. This modest overall benefit was also supported by greater odds of patients reporting a clinically meaningful improvement in HRQL with sacubitril/valsartan.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.003
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.137
Threshold uncertainty score0.863

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0070.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.277
Teacher spread0.253 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations30
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal of Heart FailureSame topicCardiovascular Function and Risk FactorsFrench-language works237,207